NCT03631836
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03631836 |
| Title | Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma (MARELLE01) |
| Acronym | MARELLE01 |
| Recruitment | Unknown status |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | Yes |
| Sponsors | Assistance Publique Hopitaux De Marseille |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | FRA |
CKB BOOST